Oral Erosive Lichen Planus Successfully Treated with Baricitinib
References
Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. ScientificWorldJournal. 2014 Jan 30;2014:742826. DOI: 10.1155/2014/742826. PMID: 24672362; PMCID: PMC3929580.
Abduelmula A, Bagit A, Mufti A, Yeung KCY, Yeung J. The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review. J Cutan Med Surg. 2023 May-Jun;27(3):271-276. DOI: 10.1177/12034754231156100. Epub 2023 Feb 23. PMID: 36815857; PMCID: PMC10291104.
Thandar Y, Maharajh R, Haffejee F, Mosam A. Treatment of cutaneous lichen planus (part 2): a review of systemic therapies. J Dermatolog Treat. 2019 Nov;30(7):633-647. DOI: 10.1080/09546634.2018.1544411. Epub 2018 Dec 11. PMID: 30451042.
Balestri R, Bortolotti R, Rech G, Girardelli CR, Zorzi MG, Magnano M. Treatment of Oral Erosive Lichen Planus With Upadacitinib. JAMA Dermatol. 2022 Apr 1;158(4):457-458. DOI: 10.1001/jamadermatol.2022.0147. PMID: 35294521.
Moussa A, Colla T, Morrison B, Sinclair R. Effective treatment of oral lichen planus with the JAK inhibitor baricitinib. Australas J Dermatol. 2022 May;63(2):276-277. DOI: 10.1111/ajd.13811. Epub 2022 Feb 25. PMID: 35213737.
Published
Issue
Section
License
Copyright (c) 2025 Samuele Savian, Roberto Maglie, Efenesia Maria Baffa, Carlo Pipitò, Vincenzina Rubino, Emiliano Antiga

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

